Related Experiment Videos
Pharmacokinetics and pharmacodynamics of rapacuronium bromide
William J Wight1, Peter M C Wright
1Academic Department of Anaesthesia, University of Newcastle upon Tyne, Royal Victoria Infirmary, UK.
Clinical Pharmacokinetics
|October 31, 2002
Summary
Rapacuronium, a neuromuscular blocking agent, offers rapid onset for tracheal intubation but carries a risk of dose-related bronchospasm. Its active metabolite and accumulation in renal failure contribute to its prolonged effects and withdrawal from the market.
Area of Science:
- Pharmacology
- Anesthesiology
- Drug Metabolism
Background:
- Rapacuronium is an aminosteroidal nondepolarising neuromuscular blocking agent (NMBA).
- It exhibits a different time course and lower potency compared to many existing NMBAs.
- Its rapid onset and favorable intubating conditions were initially promising.
Purpose of the Study:
- To evaluate the pharmacokinetic and pharmacodynamic properties of rapacuronium.
- To compare its efficacy and safety profile with other neuromuscular blocking agents.
- To understand the reasons for its clinical performance and adverse effects.
Main Methods:
- Pharmacokinetic analysis of rapacuronium and its active metabolite.
- Assessment of neuromuscular blocking effects and duration of action.
- Evaluation of intubating conditions and adverse events, including bronchospasm.
Main Results:
- Rapacuronium provides rapid and complete onset, with favorable intubating conditions at specific doses.
- An active metabolite contributes to prolonged action, especially after multiple doses or infusions.
- Dose-dependent bronchospasm was identified as a significant adverse effect, leading to market withdrawal.
Conclusions:
- Rapacuronium's rapid onset made it a potential alternative to suxamethonium for tracheal intubation.
- Its active metabolite and cumulative effects, particularly in renal impairment, influence its duration of action.
- The incidence of dose-related bronchospasm led to its withdrawal from sale, highlighting safety concerns.